Meeting
2022 ASCO Annual Meeting
Phase I study of pegylated liposomal doxorubicin in combination with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory sarcoma and other malignant solid tumors.
Authors
Suying Lu
Sun Yat-sen University Cancer Center, Guangzhou, China
Suying Lu , Juan Wang , Junting Huang , Feifei Sun , Jia Zhu , Zijun Zhen , Hui Li , Xiaofei Sun , Yizhuo Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04213612
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11519)
DOI
10.1200/JCO.2022.40.16_suppl.11519
Abstract #
11519
Poster Bd #
424
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.
First Author: Steven G. DuBois
Poster
2017 ASCO Annual Meeting
A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.
First Author: Leo Mascarenhas
Poster
2023 ASCO Annual Meeting
A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.
First Author: Lei Xiao
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto